摘要
目的:探讨孟鲁司特钠、西替利嗪、布地奈德联合应用治疗儿童咳嗽变异性哮喘的临床效果及对肺功能、安全性的影响。方法:选取2018年1月-2020年1月本院收治的儿童咳嗽变异性哮喘患儿80例。按随机数字表法将其分为对照组和观察组,各40例。对照组进行布地奈德常规治疗,观察组在对照组基础上联合孟鲁司特钠与西替利嗪治疗。比较两组疗效,治疗前后的肺功能及不良反应发生情况。结果:观察组治疗总有效率为95.00%高于对照组的77.50%(P<0.05);治疗后,两组第一秒用力呼气容积(FEV_(1))、FEV_(1)/用力肺活量(FVC)的百分比及最大呼气峰流速(peak expiratory flow,PEF)均高于治疗前,且观察组均高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:孟鲁司特钠、西替利嗪、布地奈德联合应用治疗儿童咳嗽变异性哮喘的效果较好,能有效改善患儿肺功能,且安全性较好,值得推广应用。
Objective:To investigate the clinical effect of Montelulast Sodium,Cetirizine and Budesonide combined application in the treatment of cough variant asthma in children and its effect on lung function and safety.Method:A total of 80 children with cough variant asthma admitted to our hospital from January 2018 to January 2020 were selected.According to the random number table,they were divided into control group and observation group,40 cases in each group.The control group was given Budesonide conventional treatment,and the observation group was treated with Montelukast Sodium and Cetirizine on the basis of the control group.The therapeutic effect,lung function before and after treatment and adverse reactions were compared between two groups.Result:The total effective rate of treatment in the observation group was 95.00%,it was higher than 77.50%in the control group(P<0.05).After treatment,forced expiratory volume in the first second(FEV_(1)),FEV_(1)/forced vital capacity(FVC)%and peak expiratory flow(PEF)were all higher in two groups than those of before treatment,and the observation group were higher than those of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:Combined application of Montelulast sodium,Cetirizine and budesonide in the treatment of cough variant asthma in children has a good effect,can effectively improves the pulmonary function of children,and is safe,it is worthy of promotion and application.
作者
寇志军
孙桂林
KOU Zhijun;SUN Guilin(Chaoyang Second Hospital,Chaoyang 122000,China;不详)
出处
《中国医学创新》
CAS
2021年第3期140-143,共4页
Medical Innovation of China